Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ptc Therapeutics Inc.
Headquarters: South Plainfield, NJ, United States of America
Website: http://www.ptcbio.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Matthew B. Klein, MD
Number Of Employees: 939
Enterprise Value: $2,718,385,783
PE Ratio: -11.52
Exchange/Ticker 1: NASDAQ:PTCT
Exchange/Ticker 2: N/A
Latest Market Cap: $4,298,382,336
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Jan 4, 2025
Market Access
Accelerated approval speed bump will limit access, disincentivize orphan drug development
Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 11, 2024
Data Byte
November’s FDA approvals include Autolus’ CD19 CAR T
Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer
BioCentury | Dec 10, 2024
Politics, Policy & Law
Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast
Plus: KCC2 activation nears inflection point
BioCentury | Dec 7, 2024
Data Byte
At $1B, PTC-Novartis deal ties record for cash up front
But partnership lands fourth on overall upfront payment
BioCentury | Dec 3, 2024
Deals
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more
Deals Report: Roche-Poseida, Novartis-PTC and Sarepta-Arrowhead forge large deals, as Idorsia keeps the lights on into 2025
BioCentury | Dec 2, 2024
Deals
PTC adds $1B up front, ‘more muscle’ for Huntington program via Novartis deal
Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug
BioCentury | Nov 15, 2024
Regulation
PTC wins gene therapy approval based on small, open-label trial
Biotech expects to sell voucher after winning gene therapy’s approval for AADC deficiency based on 13-patient study
Items per page:
1 - 10 of 404